CD8A and neoplasm: CA12 inhibitor dwindles TAMs infiltration and CCL8 production, attenuating tumor growth and metastasis with growing proportion of CD8+T cells, thus showing more notable efficacy in combination with anti‐PD‐1 therapy than monotherapy.37